These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2478835)

  • 1. Evaluation of cytokeratin markers to differentiate between benign and malignant prostatic tissue.
    Guinan P; Shaw M; Targonski P; Ray V; Rubenstein M
    J Surg Oncol; 1989 Nov; 42(3):175-80. PubMed ID: 2478835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of immunohistologic staining to develop a malignant index to aid in distinguishing benign from malignant prostatic tissue.
    Rubenstein M; Shaw MW; Ray V; Dubin A; McKiel CF; Guinan P
    Prostate; 1989; 14(4):383-8. PubMed ID: 2473461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An immunohistologic characterization of human prostatic atypical hyperplasia.
    Chou P; Ray V; Shaw M; Rubenstein M; Guinan P
    Urol Res; 1990; 18(3):193-6. PubMed ID: 1697711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of some selected cytokeratins and Ki67 protein in prostatic tumor: can these be used as tumor markers.
    Adisa JO; Egbujo EC; Ibrahim B; Musa B; Madukwe J
    Pan Afr Med J; 2015; 20():46. PubMed ID: 26090004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in keratin expression during the development of benign prostatic hyperplasia.
    Xue Y; Smedts F; Umbas R; Aalders TW; Debruyne FM; de la Rosette JJ; Schalken JA
    Eur Urol; 1997; 32(3):332-8. PubMed ID: 9358223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues.
    Hahn D; Simak R; Steiner GE; Handisurya A; Susani M; Marberger M
    J Urol; 2000 Aug; 164(2):506-10. PubMed ID: 10893635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential immunoreactivity of epidermal growth factor receptor in benign, dysplastic and malignant prostatic tissues.
    Ibrahim GK; Kerns BJ; MacDonald JA; Ibrahim SN; Kinney RB; Humphrey PA; Robertson CN
    J Urol; 1993 Jan; 149(1):170-3. PubMed ID: 7678041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of c-kit and kit-ligand in benign and malignant prostatic tissues.
    Simak R; Capodieci P; Cohen DW; Fair WR; Scher H; Melamed J; Drobnjak M; Heston WD; Stix U; Steiner G; Cordon-Cardo C
    Histol Histopathol; 2000 Apr; 15(2):365-74. PubMed ID: 10809354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microvessel density as a molecular marker for identifying high-grade prostatic intraepithelial neoplasia precursors to prostate cancer.
    Sinha AA; Quast BJ; Reddy PK; Lall V; Wilson MJ; Qian J; Bostwick DG
    Exp Mol Pathol; 2004 Oct; 77(2):153-9. PubMed ID: 15351240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential immunoreactivity of transforming growth factor alpha in benign, dysplastic and malignant prostatic tissues.
    Robertson CN; Roberson KM; Herzberg AJ; Kerns BJ; Dodge RK; Paulson DF
    Surg Oncol; 1994 Aug; 3(4):237-42. PubMed ID: 7530564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stem cell features of benign and malignant prostate epithelial cells.
    De Marzo AM; Nelson WG; Meeker AK; Coffey DS
    J Urol; 1998 Dec; 160(6 Pt 2):2381-92. PubMed ID: 9817389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate.
    Kirschenbaum A; Klausner AP; Lee R; Unger P; Yao S; Liu XH; Levine AC
    Urology; 2000 Oct; 56(4):671-6. PubMed ID: 11018637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis.
    Di Silverio F; Gentile V; De Matteis A; Mariotti G; Giuseppe V; Luigi PA; Sciarra A
    Eur Urol; 2003 Feb; 43(2):164-75. PubMed ID: 12565775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there a relationship between benign prostatic hyperplasia and prostatic cancer?
    Pagano F; Zattoni F; Vianello F; Piazza R; Capitanio G
    Eur Urol; 1991; 20 Suppl 1():31-5. PubMed ID: 1722159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia.
    Theyer G; Kramer G; Assmann I; Sherwood E; Preinfalk W; Marberger M; Zechner O; Steiner GE
    Lab Invest; 1992 Jan; 66(1):96-107. PubMed ID: 1370561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cells in various benign and malignant conditions of the human prostate express different antigenic phenotypes.
    Turhan OI; Aydin NE; Sariyüce O; Ozkan S
    Int Urol Nephrol; 1998; 30(6):731-44. PubMed ID: 10195869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial and prostatic marker expression in short-term primary cultures of human prostate tissue samples.
    Festuccia C; Angelucci A; Gravina GL; Muzi P; Miano R; Vicentini C; Bologna M
    Int J Oncol; 2005 May; 26(5):1353-62. PubMed ID: 15809728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis of prostate carcinoma on biopsy specimens improved by basal-cell-specific anti-cytokeratin antibody (34 beta E12).
    Freibauer C
    Wien Klin Wochenschr; 1998 Sep; 110(17):608-11. PubMed ID: 9816630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cathepsin B in angiogenesis of human prostate: an immunohistochemical and immunoelectron microscopic analysis.
    Sinha AA; Gleason DF; Staley NA; Wilson MJ; Sameni M; Sloane BF
    Anat Rec; 1995 Mar; 241(3):353-62. PubMed ID: 7538734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Keratin immunoreactivity in the benign and neoplastic human prostate.
    Brawer MK; Peehl DM; Stamey TA; Bostwick DG
    Cancer Res; 1985 Aug; 45(8):3663-7. PubMed ID: 2410099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.